RedHill has received from the European Patent Office a Notice of Intention to Grant a new patent covering RHB104 for multiple sclerosis MS expected to be valid until 2032 once granted A Phase IIa proofofconcept study evaluating RHB104 in patients treat...
↧
RedHill Biopharma Announces Approval of a European Patent Supporting RHB104 for Multiple Sclerosis
↧